SILVER SPRING
Dupixent cleared for pediatric chronic spontaneous urticaria
- Sponsor
- Sanofi and Regeneron
- Drug
- Dupixent · dupilumab
- Indication
- chronic spontaneous urticaria in children
FDA approved Dupixent (dupilumab) for children aged two to 11 years with chronic spontaneous urticaria who remain symptomatic despite antihistamine treatment.
What this means
Dupixent is an injectable antibody drug that blocks two proteins involved in allergic inflammation, helping control symptoms like hives and itching. Today FDA approved Dupixent for children aged two to 11 with chronic spontaneous urticaria who still have symptoms after taking antihistamines. This decision could provide younger patients with a new treatment option for persistent hives that don’t respond to standard therapies.
Drug Watch — recent news on Dupixent
- Sanofi Eyes €25B Dupixent Future, Expands M&A Hunt Ahead of Patent Loss - Yahoo Finance
- Dupilumab May Ease Ear Inflammation in Severe CRSwNP - Medscape
- Delayed Dupilumab Raises Asthma Costs 32%: Nicola Hanania, MD - ajmc.com
- Earlier Dupilumab Use Cuts Asthma Costs: Nicola Hanania, MD - ajmc.com
- Connect's Dupixent rival flunks phase 2 asthma trial, but biotech sees reasons for hope - Fierce Biotech
Sponsor Watch — recent news on Sanofi and Regeneron
- Sanofi Eyes €25B Dupixent Future, Expands M&A Hunt Ahead of Patent Loss
- In Vivo Gene Editing Market Size, Share & Trends Analysis - Global Opportunity Analysis & Industry Forecast (2026-2036)
- Can Intellia's Pipeline Progress Create Long-Term Value Amid Rivalry?
- Paroxysmal Nocturnal Hemoglobinuria Market Forecast Upto 2036: 5 Emerging Therapies Poised to Accelerate Market Growth | DelveInsight
- FDA Approves Label Expansion of BAYRY's Kidney Disease Drug Kerendia